SecBot SecBot
8-K ·Filed May 6, 2026

ACAD

ACADIA PHARMACEUTICALS INC
BEARISH
Impact 6/10
Horizondays Processed6mo ago SEC0001193125-26-209253
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

EPS miss of 75% vs consensus will pressure the stock near-term. Monitor analyst reactions and any cost control initiatives. The DAYBUE growth and guidance reaffirmation provide a floor, but rising SG&A is a concern.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.56
T+0 close · May 6, 2026 · via day close
Latest settled
+13.52%
T+60 · $25.61
Vs SPY
+9.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $22.56entry
  2. T+1 · 6mo ago 0.00%α −0.83% · $22.56
  3. T+5 · 6mo ago −1.68%α −3.19% · $22.18
  4. T+20 · 6mo ago −5.01%α −8.14% · $21.43
  5. T+60 · 4mo ago +13.52%α +9.69% · $25.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (vs $280.3M est). Revenue grew 10% YoY, but EPS fell 82% YoY due to a 36% surge in SG&A expenses. Full-year 2026 guidance was reaffirmed, providing some stability.

Key Financial Metrics

EPS
$0.02
est $0.08 · -75.0%
Revenue
$268.1M
est $280.3M · -4.4% · +9.7% YoY
Rating
miss
Guidance
$1.22B-$1.28B
maintained

Key Facts

  • Q1 2026 GAAP revenue $268M, up 10% YoY from $244M
  • Q1 2026 GAAP diluted EPS $0.02, down 82% from $0.11 YoY
  • SG&A expense $171M, up 36% from $126M YoY, driving operating loss
  • DAYBUE net sales $101M (+20% YoY), NUPLAZID $167M (+5% GAAP, +6% adjusted)
  • Full-year 2026 guidance reaffirmed: revenue $1.22-1.28B

Financial Impact

EPS miss of 75% vs consensus ($0.02 actual vs $0.08 est); revenue miss of ~4%

epsnetIncomeoperatingIncome

Risk Factors

  • Continued SG&A cost inflation without corresponding revenue acceleration
  • Remlifanserin Phase 2 data risk (readout Aug-Oct 2026)
  • IRA rebate adjustments may cause further earnings volatility

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-209253
Document: acad-20260506.htm0001193125-26-209253
Document: 0001193125-26-209253-index-headers.html0001193125-26-209253
Document: 0001193125-26-209253-index.html0001193125-26-209253
Document: 0001193125-26-209253.txt0001193125-26-209253
8-K Data (Synthetic)0001193125-26-209253

Track record

14 reports on ACAD

Performance horizon

0 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +1.40% at T+1 after the Jun 11, 2026 report. 1 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
  2. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
  4. Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
  5. Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
  7. Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
  8. Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
  10. May 6, 202627w ago 8-K Bearish 6/10 Viewing Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026